Adjuvant Nivolumab Improved DFS in Esophageal and GEJ Cancers
Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.
Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.
Researchers sought to determine if LNG-IUD is effective and whether the addition of weight loss or metformin can further improve response in patients with EAC and EHA.
Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
Investigators report findings from the RATIONALE307 trial that assessed treatment with tislelizumab in patients with squamous NSCLC.
A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
A team of investigators conducted a retrospective study to determine the relationship of intrinsic breast cancer subtypes on survival in patients undergoing endocrine therapy plus ribociclib.
Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.
Investigators deployed a survey to assess burnout, stress, emotional wellbeing, and pandemic experiences among pediatric hematology/oncology providers and staff.
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.